Compare MBAI & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBAI | IMRN |
|---|---|---|
| Founded | 2004 | 1994 |
| Country | Israel | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 9.6M |
| IPO Year | 2014 | 2016 |
| Metric | MBAI | IMRN |
|---|---|---|
| Price | $6.30 | $1.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 61.4K | ★ 3.2M |
| Earning Date | 05-12-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $0.68 |
| 52 Week High | $10.21 | $2.38 |
| Indicator | MBAI | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 58.95 | 79.62 |
| Support Level | $1.19 | $1.00 |
| Resistance Level | $10.21 | N/A |
| Average True Range (ATR) | 0.37 | 0.10 |
| MACD | -0.31 | 0.07 |
| Stochastic Oscillator | 11.04 | 84.92 |
MBody AI Ltd is an embodied artificial intelligence company. Its core technology is the MBody AI Orchestrator (Orchestrator), a proprietary, hardware-agnostic software platform that serves as an intelligence layer designed to enable autonomous systems to operate, coordinate, and improve more effectively. MBody AI does not manufacture robots; it makes third-party robots more intelligent and coordinated through the Orchestrator and deploys them at customer sites together with its software and related services. Each deployment is designed to generate proprietary operational data. Its initial commercial focus is the hospitality industry, with potential applications across other labor-intensive sectors, including warehousing, office management, and healthcare.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.